Atezolizumab/nivolumab/pembrolizumabOral lichenoid reactions: 10 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2017年 / 1681卷 / 1期

关键词：

D O I：

10.1007/s40278-017-39337-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：61 / 61

相关论文

共 50 条

[1] Atezolizumab/nivolumab/pembrolizumabInverse lichenoid eruption: 2 case reports
[J]. Reactions Weekly, 2021, 1860 (1) : 75 - 75
[2] Atezolizumab/nivolumab/pembrolizumabVarious toxicities: 10 case reports
[J]. Reactions Weekly, 2023, 1963 (1) : 101 - 101
[3] Nivolumab/pembrolizumabOral mucositis and fatigue: 3 case reports
[J]. Reactions Weekly, 2021, 1871 (1) : 328 - 328
[4] PembrolizumabOral lichenoid reaction: case report
[J]. Reactions Weekly, 2022, 1918 (1) : 409 - 409
[5] Atezolizumab/nivolumab/pembrolizumabPsoriasis: 17 case reports
[J]. Reactions Weekly, 2017, 1658 (1) : 62 - 62
[6] Atezolizumab/nivolumab/pembrolizumabPanniculitis: 5 case reports
[J]. Reactions Weekly, 2022, 1929 (1) : 116 - 116
[7] Atezolizumab/nivolumab/pembrolizumabMusculoskeletal disorders: 9 case reports
[J]. Reactions Weekly, 2022, 1887 (1) : 112 - 112
[8] Atezolizumab/nivolumab/pembrolizumabPericardial effusion: 14 case reports
[J]. Reactions Weekly, 2019, 1749 (1) : 78 - 78
[9] Atezolizumab/nivolumab/pembrolizumabVarious toxicities: 35 case reports
[J]. Reactions Weekly, 2019, 1740 (1) : 52 - 52
[10] Atezolizumab/nivolumab/pembrolizumabVarious toxicities: 9 case reports
[J]. Reactions Weekly, 2020, 1806 (1) : 59 - 59

← 1 2 3 4 5 →